I have a bachelor’s degree in biomedical sciences from the University of Tromsø and am currently working on my master project in the Brain Tumour Immunology group at the University of Bergen.
Using CRISPR/Cas9 to introduce a novel mutation in CSPG4 in glioblastoma cells and characterising the phenotype
My project centres around glioblastoma (GBM), a highly aggressive brain tumour, and NG2/CSPG4, a proteoglycan my group has shown to be an independently bad prognostic factor in GBM. Approximately 58% of GBM patient biopsies have been shown to highly express NG2, promoting angiogenesis and vascularisation, resulting in shorter overall survival. My aim is to introduce a novel mutation in the CSPG4 gene in long-term established GBM cell lines as well as primary GBM cells, and characterise the phenotype. The introduction of the mutation will be achieved via an optimised CRISPR/Cas9 technique that specifically alters the gene of interest. Once the mutation is confirmed from single-cell derived colonies, the phenotype will be characterised via functional assays that relate to cell growth, vascularisation and pathways that are known to be affected by NG2/CSPG4.